Reply to ‘The shift of therapeutic strategy for prolactinomas: surgery as the first-line option’

IF 31 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Nature Reviews Endocrinology Pub Date : 2024-01-22 DOI:10.1038/s41574-024-00954-4

Stephan Petersenn, Maria Fleseriu, Shlomo Melmed

引用次数: 0

查看原文本刊更多论文

对 "泌乳素瘤治疗策略的转变：手术作为一线选择 "的回复。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Endocrinology 医学-内分泌学与代谢

CiteScore

42.00

自引率

0.70%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.